Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of LifeMD, Inc. (LFMD)

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of (NASDAQ: LFMD) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to the dates listed below may have standing to seek corporate governance reforms focused on executive oversight, the return of funds to the Company, and a court-approved incentive award, at no cost to them.

If you have held LifeMD shares continuously since prior to May 7, 2025, you may have standing to seek corporate governance reforms focused on executive oversight at LifeMD.

To learn more, contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471.

Complaint Allegations
A previously filed securities class action complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) LifeMD’s competitive position was materially overstated; (2) Defendants were reckless in raising the Company’s 2025 guidance without adequately accounting for rising customer acquisition costs in LifeMD’s RexMD segment and customer acquisition costs associated with the sale of obesity drugs, including Wegovy and Zepbound; and (3) as a result, Defendants’ statements regarding the Company’s business, operations, and prospects were materially false or misleading and/or lacked a reasonable basis.